

Table 3.6
Verified Primary and Other Cancers (Annualized Percentages): MRC and SRC Super Cohort Participants
 Data as of: February 19, 2022; Events through February 19, 2022

	Total		MRC Super Cohort ¹		SRC Super Cohort ²	
Number of participants	161808		44174		117634	
Mean follow-up (months)	203.4		189.8		208.5	
Overall cancer	36778	(1.34%)	8578	(1.23%)	28200	(1.38%)
Primary cancer						
Breast cancer	14181	(0.52%)	3094	(0.44%)	11087	(0.54%)
Invasive breast cancer	11897	(0.43%)	2552	(0.37%)	9345	(0.46%)
In situ breast cancer	2539	(0.09%)	604	(0.09%)	1935	(0.09%)
Ovarian cancer	1372	(0.05%)	292	(0.04%)	1080	(0.05%)
Endometrial cancer ³	1926	(0.12%)	351	(0.09%)	1575	(0.13%)
Colorectal cancer	3605	(0.13%)	1005	(0.14%)	2600	(0.13%)
Other cancer						
Accessory sinus	16	(<0.01%)	3	(<0.01%)	13	(<0.01%)
Adrenal gland	18	(<0.01%)	5	(<0.01%)	13	(<0.01%)
Anus	142	(0.01%)	33	(<0.01%)	109	(0.01%)
Appendix	52	(<0.01%)	14	(<0.01%)	38	(<0.01%)
Base of tongue	38	(<0.01%)	9	(<0.01%)	29	(<0.01%)
Biliary tract, parts of (other/unspecified)	213	(0.01%)	64	(0.01%)	149	(0.01%)
Bladder	1146	(0.04%)	277	(0.04%)	869	(0.04%)
Bones/joints/articular cartilage (limbs)	14	(<0.01%)	2	(<0.01%)	12	(<0.01%)
Bones/joints/articular cartilage (other)	32	(<0.01%)	9	(<0.01%)	23	(<0.01%)
Brain	419	(0.02%)	77	(0.01%)	342	(0.02%)
Cervix	138	(0.01%)	45	(0.01%)	93	(<0.01%)
Central Nervous System (excludes brain)	5	(<0.01%)	1	(<0.01%)	4	(<0.01%)
Connective/subcutaneous/soft tissues	214	(0.01%)	47	(0.01%)	167	(0.01%)
Endocrine glands, related structures	5	(<0.01%)	0	(0.00%)	5	(<0.01%)
Esophagus	206	(0.01%)	52	(0.01%)	154	(0.01%)
Eye and adnexa	83	(<0.01%)	24	(<0.01%)	59	(<0.01%)
Floor of Mouth	20	(<0.01%)	8	(<0.01%)	12	(<0.01%)
Gallbladder	156	(0.01%)	49	(0.01%)	107	(0.01%)
Genital organs ⁴	180	(0.01%)	26	(<0.01%)	154	(0.01%)
Gum	52	(<0.01%)	8	(<0.01%)	44	(<0.01%)
Heart	42	(<0.01%)	6	(<0.01%)	36	(<0.01%)
Kidney	825	(0.03%)	223	(0.03%)	602	(0.03%)
Larynx	56	(<0.01%)	21	(<0.01%)	35	(<0.01%)
Leukemia	1277	(0.05%)	294	(0.04%)	983	(0.05%)
Liver	376	(0.01%)	108	(0.02%)	268	(0.01%)
Lung	4535	(0.17%)	1232	(0.18%)	3303	(0.16%)
Lymph nodes	3	(<0.01%)	1	(<0.01%)	2	(<0.01%)
Lymphoma, Hodgkins	84	(<0.01%)	24	(<0.01%)	60	(<0.01%)
Lymphoma, non-Hodgkins	1997	(0.07%)	411	(0.06%)	1586	(0.08%)
Melanoma of the skin	2855	(0.10%)	416	(0.06%)	2439	(0.12%)
Meninges	8	(<0.01%)	2	(<0.01%)	6	(<0.01%)
Multiple myeloma	701	(0.03%)	223	(0.03%)	478	(0.02%)
Mycosis fungoides	30	(<0.01%)	8	(<0.01%)	22	(<0.01%)
Nasal cavity mid ear	22	(<0.01%)	3	(<0.01%)	19	(<0.01%)
Oral (mouth)	46	(<0.01%)	8	(<0.01%)	38	(<0.01%)
Other digestive cancer	67	(<0.01%)	14	(<0.01%)	53	(<0.01%)
Other lip	17	(<0.01%)	7	(<0.01%)	10	(<0.01%)
Palate	36	(<0.01%)	8	(<0.01%)	28	(<0.01%)

¹ The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.

² The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

³ Only women without a baseline hysterectomy are used to compute the annual rates of endometrial and uterine cancer.

⁴ Vaginal and vulvar cancers were included with genital organ cancers in prior reports. As of 2022, these cancers are now shown separately.

Table 3.6 (continued)
Verified Primary and Other Cancers (Annualized Percentages): MRC and SRC Super Cohort Participants

Data as of: February 19, 2022; Events through February 19, 2022;

	Total		MRC Super Cohort ¹		SRC Super Cohort ²	
Number of participants	161808		44174		117634	
Mean follow-up (months)	203.4		189.8		208.5	
Pancreas	1445	(0.05%)	376	(0.05%)	1069	(0.05%)
Parotid gland (Stensen's duct)	72	(<0.01%)	16	(<0.01%)	56	(<0.01%)
Peripheral nerves and autonomic nervous	2	(<0.01%)	0	(0.00%)	2	(<0.01%)
Peritoneum	242	(0.01%)	54	(0.01%)	188	(0.01%)
Pharynx	32	(<0.01%)	12	(<0.01%)	20	(<0.01%)
Pyramidal sinus	2	(<0.01%)	0	(0.00%)	2	(<0.01%)
Renal pelvis	146	(0.01%)	39	(0.01%)	107	(0.01%)
Respiratory system, intrathoracic, other	3	(<0.01%)	0	(0.00%)	3	(<0.01%)
Salivary glands, major (other/unspecified)	19	(<0.01%)	4	(<0.01%)	15	(<0.01%)
Small intestine	176	(0.01%)	43	(0.01%)	133	(0.01%)
Stomach	335	(0.01%)	108	(0.02%)	227	(0.01%)
Thymus	15	(<0.01%)	3	(<0.01%)	12	(<0.01%)
Thyroid	529	(0.02%)	112	(0.02%)	417	(0.02%)
Tongue, part of (other/unspecified)	94	(<0.01%)	15	(<0.01%)	79	(<0.01%)
Tonsil	25	(<0.01%)	3	(<0.01%)	22	(<0.01%)
Trachea	1	(<0.01%)	1	(<0.01%)	0	(0.00%)
Ureter	91	(<0.01%)	20	(<0.01%)	71	(<0.01%)
Urinary organs (other/unspecified)	40	(<0.01%)	13	(<0.01%)	27	(<0.01%)
Uterus, not otherwise specified ³	151	(0.01%)	36	(0.01%)	115	(0.01%)
Vagina ⁴	52	(<0.01%)	13	(<0.01%)	39	(<0.01%)
Vulva ⁴	193	(0.01%)	49	(0.01%)	144	(0.01%)
Other/unknown site of cancer	595	(0.02%)	144	(0.02%)	451	(0.02%)
Other/unknown cancers reported on death	523	(0.02%)	101	(0.01%)	422	(0.02%)

¹ The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.

² The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown race/ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

³ Only women without a baseline hysterectomy are used to compute the annual rates of endometrial and uterine cancer.

⁴ Vaginal and vulvar cancers were included with genital organ cancers in prior reports. As of 2022, these cancers are now shown separately.